Clover Health Investments, Corp. (CLOV)
NASDAQ: CLOV · Real-Time Price · USD
2.580
-0.080 (-3.01%)
At close: Dec 5, 2025, 4:00 PM EST
2.628
+0.048 (1.84%)
After-hours: Dec 5, 2025, 7:47 PM EST
Clover Health Investments Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Clover Health Investments stock ranges from a low of $3.00 to a high of $6.00. The average analyst price target of $4.23 forecasts a 63.95% increase in the stock price over the next year.
Price Target: $4.23 (+63.95%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for Clover Health Investments stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.1 → $3.7 | Strong Buy | Maintains | $4.1 → $3.7 | +43.41% | Nov 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.5 → $4.1 | Strong Buy | Maintains | $4.5 → $4.1 | +58.91% | Aug 7, 2025 |
| UBS | UBS | Hold Maintains $4.5 → $3 | Hold | Maintains | $4.5 → $3 | +16.28% | Aug 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $4.2 → $4.5 | Strong Buy | Maintains | $4.2 → $4.5 | +74.42% | Mar 3, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +132.56% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
1.94B
from 1.37B
Increased by 41.68%
Revenue Next Year
2.67B
from 1.94B
Increased by 37.69%
EPS This Year
-0.18
from -0.09
EPS Next Year
-0.03
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.0B | 2.9B | ||||
| Avg | 1.9B | 2.7B | ||||
| Low | 1.9B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 46.4% | 47.2% | ||||
| Avg | 41.7% | 37.7% | ||||
| Low | 35.2% | 27.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.18 | 0.02 | |||
| Avg | -0.18 | -0.03 | |||
| Low | -0.18 | -0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.